

INSUFFICIENZA MITRALICA DEGENERATIVA 1

DIAGNOSI e RIMEDI a CUORE APERTO

Anche la plastica tradizionale della insufficienza mitralica è evoluta
I criteri della chirurgia sono cambiati? Cenni di tecnica

Lucia Torracca

PRIMA X CONGRESSO NAZIONALE X CONGRESSO NAZIONALE X CONGRESSO NAZIONALE X CONGRESSO NAZIONALE X CONGRESSO NAZIONALE
X CONGRESSO NAZIONALE X CONGRESSO NAZIONALE X CONGRESSO NAZIONALE X CONGRESSO NAZIONALE X CONGRESSO NAZIONALE
**X CONGRESSO NAZIONALE
ECOCARDIOCHIRURGIA 2018**
da un'idea di Antonio Mantero
MILANO, 9-11 APRILE 2018

PROGRAMMA AVANZATO

**CENTRO CONGRESSI
PALAZZO DELLE STELLINE
CORSO MAGENTA, 61
20123 MILANO**

**SEGRETERIA ORGANIZZATIVA
VICTORY PROJECT CONGRESSI
VIA C. POMA, 2 - 20129 MILANO
TEL. 02 89 05 35 24
FAX 02 20 13 95
INFO@VICTORYPROJECT.IT**

**PRESIDENTE ONORARIO
GIUSEPPE TARELLI**
**PRESIDENTE
ANTONIO MANTERO**

**DIRETTORI
FRANCESCO ALAMANNI
GIOVANNI CORRADO**

**COORDINATORI ESECUTIVI
ANDREA BELLONE
EMANUELE CATENA
CORRADO LETTIERI**



HUMANITAS
RESEARCH HOSPITAL

Indications for intervention in severe primary mitral regurgitation

Recommendations	Class ^a	Level ^b
Mitral valve repair should be the preferred technique when the results are expected to be durable.	I	C
Surgery is indicated in symptomatic patients with LVEF >30%. ^{121,131,132}	I	B
Surgery is indicated in asymptomatic patients with LV dysfunction (LVESD ≥45 mm ^c and/or LVEF ≤60%). ^{122,131}	I	B
Surgery should be considered in asymptomatic patients with preserved LV function (LVESD <45 mm and LVEF >60%) and atrial fibrillation secondary to mitral regurgitation or pulmonary hypertension ^d (systolic pulmonary pressure at rest >50 mmHg). ^{123,124}	IIa	B
Surgery should be considered in asymptomatic patients with preserved LVEF (>60%) and LVESD 40–44 mm ^c when a durable repair is likely, surgical risk is low, the repair is performed in a heart valve centre and at least one of the following findings is present: <ul style="list-style-type: none"> flail leaflet or presence of significant LA dilatation (volume index ≥60 mL/m² BSA) in sinus rhythm. 	IIa	C
Mitral valve repair should be considered in symptomatic patients with severe LV dysfunction (LVEF <30% and/or LVESD >55 mm) refractory to medical therapy when the likelihood of successful repair is high and comorbidity low.	IIa	C
Mitral valve replacement may be considered in symptomatic patients with severe LV dysfunction (LVEF <30% and/or LVESD >55 mm) refractory to medical therapy when the likelihood of successful repair is low and comorbidity low.	IIb	C
Percutaneous edge-to-edge procedure may be considered in patients with symptomatic severe primary mitral regurgitation who fulfil the echocardiographic criteria of eligibility and are judged inoperable or at high surgical risk by the Heart Team, avoiding futility.	IIb	C

Table 12 Indications for surgery in severe primary mitral regurgitation

	Class ^a	Level ^b	Ref ^c
Mitral valve repair should be the preferred technique when it is expected to be durable.	I	C	
Surgery is indicated in symptomatic patients with LVEF >30% and LVESD <55 mm.	I	B	127, 128
Surgery is indicated in asymptomatic patients with LV dysfunction (LVESD ≥45 mm and/or LVEF ≤60%).	I	C	
Surgery should be considered in asymptomatic patients with preserved LV function and new onset of atrial fibrillation or pulmonary hypertension (systolic pulmonary pressure at rest >50 mmHg).	IIa	C	
Surgery should be considered in asymptomatic patients with preserved LV function, high likelihood of durable repair, low surgical risk and flail leaflet and LVESD ≥40 mm.	IIa	C	
Surgery should be considered in patients with severe LV dysfunction (LVEF <30% and/or LVESD >55 mm) refractory to medical therapy with high likelihood of durable repair and low comorbidity.	IIa	C	
Surgery may be considered in patients with severe LV dysfunction (LVEF <30% and/or LVESD >55 mm) refractory to medical therapy with low likelihood of durable repair and low comorbidity.	IIb	C	
Surgery may be considered in asymptomatic patients with preserved LV function, high likelihood of durable repair, low surgical risk, and: <ul style="list-style-type: none"> left atrial dilatation (volume index ≥60 mL/m² BSA) and sinus rhythm, or pulmonary hypertension on exercise (SPAP ≥60 mmHg at exercise). 	IIb	C	

ESC
GL
2
0
1
7




ESC
GL
2
0
1
2

610 patients , severe MR, normal ventricular function, no symptoms (prospective study)

- 235 early surgery
- 375 conventional treatment

- 207 propensity matched pairs

Comparison of end points in a propensity-matched cohort




Association Between Early Surgical Intervention vs Watchful Waiting and Outcomes for Mitral Regurgitation Due to Flail Mitral Valve Leaflets

Rakesh M. Suri, MD, DPhil; Jean-Louis Vanovershelde, MD; Francesco Grigioni, MD, PhD; Hartzell V. Schaff, MD; Christophe Tribouilloy, MD; Jean-Francois Avierinos, MD; Andrea Barbieri, MD; Agnes Pasquet, MD; Marianne Huebner, PhD; Dan Rusinaru, MD; Antonio Russo, MD; Hector I. Michelena, MD; Maurice Enriquez-Sarano, MD


- Registro internazionale**
- **1021** pazienti
 - **648** propensity matched
 - **Follow-up 5 anni**

Figure 1. Survival After Diagnosis of Mitral Regurgitation Due to Flail Mitral Leaflet According to Initial Treatment Strategy




Long-term survival following early surgery vs initial medical management overall population (A) and in the propensity score-matched cohort (B).

Figure 2. Heart Failure Incidence After Diagnosis of Mitral Regurgitation Due to Flail Mitral Leaflet According to Initial Treatment Strategy




Long-term heart failure risk following early surgery vs initial medical management overall (A) and in the propensity score-matched cohort (B).

Long-term follow-up of asymptomatic or mildly symptomatic patients with severe degenerative mitral regurgitation and preserved left ventricular function




Afib and Pulmonary Artery Pressure and Outcome



	0	5	10	15	20
No AF/PHT	106	70	29	9	2
AF/PHT	106	66	28	8	4


A



Pts < 65 yrs old

	0	5	10	15	20
No AF/PHT	54	37	18	6	2
AF/PHT	50	33	14	6	3

B




Pts > 65 yrs old

	0	5	10	15	20
No AF/PHT	52	33	11	3	0
AF/PHT	56	33	14	2	1

C

Afib, Pulmonary pressure and repair durability



Impact of Left Atrial Volume on Clinical Outcome in Organic Mitral Regurgitation

Le Tourneau JACC 2010




Figure 1 Survival After Diagnosis According to LA Volume




Figure 5 Outcome in Patients With Markedly Enlarged LA Compared Between Surgical and Medical Management

Longitudinal Outcome of Isolated Mitral Repair in Older Patients: Results From 14,604 Procedures Performed From 1991 to 2007






Table 3. Impact of Preoperative New York Heart Association Class on Operative Mortality After Isolated Primary Mitral Valve Repair in Patients Aged 65 Years or More

Age Group	Total Cohort	NYHA I-II	NYHA III-IV	<i>p</i> Value
Overall	2.6%	1.5%	3.3%	<0.0001
65 to 70 years	1.7%	0.8%	2.4%	<0.0001
70 to 75 years	1.9%	1.2%	2.3%	0.0047
75 to 80 years	3.4%	2.5%	4.0%	0.0165
More than 80 years	4.3%	2.7%	5.3%	0.0060

NYHA = New York Heart Association.



Impact of preoperative Afib on 5 years readmission for HF

Mitral repair: early surgery

- Probability of repair $> 95\%$
- Low mortality $< 1\%$
- **DURABLE REPAIR**



Il concetto di «repair rate»

- Monitoraggio della percentuale di valvole riparate con successo rispetto al numero totale di pazienti operati per insufficienza mitralica degenerativa
- Valutazione ecocardiografica della eziologia e del meccanismo del vizio valvolare
- Controllo ecocardiografico postoperatorio del risultato della riparazione


La nostra esperienza

- AA 2016-2017
- Chirurgia della valvola mitrale: 386
- Malattia degenerativa della valvola mitrale: 234
- Riparazione valvolare 227
- «repair rate» 97%
- Mortalità 0.5%

Late results of Minimally Invasive Mitral Repair in Barlow disease



Quale tecnica chirurgica?



Surgical techniques:

- **Posterior leaflet** prolapse/flail: resection, neocordae implantation
- **Anterior leaflet** prolapse/flail: neocordae implantation
- **Bileaflet** prolapse/flail: resection, neocordae implantation/ edge-to-edge

How does the use of polytetrafluoroethylene neochordae for posterior mitral valve prolapse (loop technique) compare with leaflet resection? A prospective randomized trial

TABLE 5. Echocardiographic follow-up

6-mo follow-up	Loops (n = 42)	Resection (n = 34)
LVEF	60.4 ± 7.9	57.3 ± 7.9
MR grade	0.21 ± 0.4	0.32 ± 0.42
<i>P</i> mean (mm Hg)	2.36 ± 0.97	2.44 ± 1.23
Mitral orifice area (cm ²)	3.27 ± 1.32	2.96 ± 1.01
1-y follow-up	Loops (n = 30)	Resection (n = 20)
LVEF	62.9 ± 8.3	59 ± 12.3
MR grade	0.28 ± 0.45	0.44 ± 0.54
<i>P</i> mean (mm Hg)	2.34 ± 0.96	2.58 ± 1.39
Mitral orifice area (cm ²)	3.21 ± 1.39	3.62 ± 1.35

LVEF, Left ventricular ejection fraction; *MR*, mitral regurgitation. All values are expressed as mean ± standard deviation.

No difference

Line of coaptation (mm)	Loops	Resection	
After surgery	7.6 ± 3.6 mm	5.9 ± 2.6 mm	<i>P</i> = .03

Table 4. Echocardiographic Outcomes Before and Immediately After Surgery

	Baseline	After Surgery	<i>p</i> Value
MR grade			
Loop	3.3 ± 0.7	0.2 ± 0.5	< 0.001
Resection	3.3 ± 0.6	0.4 ± 0.6	< 0.001
<i>p</i> value	0.5	0.007	
LVEF, %			
Loop	63.9 ± 10.5	58.2 ± 9.3	< 0.001
Resection	60.9 ± 12.6	56.6 ± 11.1	< 0.001
<i>p</i> value	0.19	0.08	
<u>Mitral orifice area, cm²</u>			
Loop		3.3 ± 0.8	
Resection		3.0 ± 0.8	
<i>p</i> value		< 0.001	
<u>P mean, mm Hg</u>			
Loop		2.7 ± 1.7	
Resection		3.1 ± 1.7	
<i>p</i> value		0.03	

All data are presented as mean ± standard deviation.


LVEF = left ventricular ejection fraction; MR = mitral regurgitation; P mean = mean pressure gradient.

Leaflet resection versus cordal replacement in posterior leaflet prolapse

1708 MIMVR pts

- 353 Leaflet resection
- 317 cordal replacement

Post-repair coaptation length and durability of mitral valve repair for posterior mitral valve prolapse



Patients	43	39	22	12	9	6	4	Group A
at risk	76	65	40	31	22	14	7	Group B

Group A : postrepair CL \geq 8mm

Group B : postrepair CL < 8mm

Eco adulti

X8-2t
16Hz
20cm

2D
61%
C 50
P Off
Gen.

CF
45%
4666Hz
WF 419Hz
3.3MHz



PAT T: 37.0C
Temp. TEE: 39.8C


TISO.5

MI 0.5



P

M4 M4
+53.9



-53.9
cm/s

T x3

*** bpm

Eco adulti

TIS0.7

MI 0.3

X8-2t
15Hz
17cm

0 145 180

2D
60%
C 50
P Off
Gen.

CF
48%
6390Hz
WF 575Hz
4.4MHz



PAT T: 37.0C
Temp. TEE: 40.1C



*** bpm

PHILIPS

26/02/2018

12:17:21

TISO.1

MI 0.5

25/08/1962 PROLASSO VM

X7-2t/AdultI

FR 52Hz

10cm

M4

2D

85%

C 50

P Off

Gen



JPEG

Temp. PAZ.: 37.0C

Temp. TEE: 39.1C

*** bpm

PHILIPS

26/02/2018 17:24:13

TIS0.4 MI 0.7

25/08/1962 PROLASSO VM



X7-2t/AdultI

FR 14Hz
8.1cm

2D
71%
C 50
P Off
Gen



CF
59%
4.4MHz
WF Max.
Med.





JPEG

Temp. PAZ.: 37.0C
Temp. TEE: 39.3C

*** bpm

Mechanism of and Risk Factors for Reoperation After Mitral Valve Repair for Degenerative Mitral Regurgitation

Circulation J 2013



No difference in reoperation or recurrence rate depending on location of the prolapse

Mitral repair failure: risk factors and mechanism

Table 4. Risk Factors for Reoperation


Multivariate

Moderate MR at discharge	3.246	1.297–8.117	0.012
LVDd	3.009	1.441–6.278	0.003

- Procedure-related: ring dehiscence, neo cordae rupture, tear of suture (EARLY)
- Valve related: new prolapse, leaflet thickening (IM,SM), endocarditis

Il ruolo dell'anuloplastica

	All (n=110)	Group1 Mean MV Grade ≤3 mmHg (n=35)	Group 2 Mean MV Grade >3 mmHg (n=75)	P Value
Resting measures				
MV peak gradient, mm Hg	10.0±4.4	6.5±1.2	11.7±4.5	<0.0001
MV mean gradient, mm Hg	4.5±2.4	2.5±0.3	5.5±2.4	...
MV area, cm ²	2.1±0.6	2.4±0.5	1.9±0.6	0.0005
PASP, mm Hg	33.3±9.6	28.6±5.7	35.5±10.2	.0003
Peak exercise measures				
MV peak gradient, mm Hg	21.9±10.1	15.6±6.4	24.8±10.2	<0.0001
MV mean gradient, mm Hg	12.5±6.7	8.9±3.8	14.2±7.1	<0.0001
MV annuloplasty	107 (97)	33 (94)	74 (99)	
Band	65 (59)	32 (91)	33 (44)	<0.0001
Ring	42 (38)	1 (3)	41 (55)	<0.0001



Conclusioni

- La riparazione valvolare mitralica è il trattamento di scelta della insufficienza mitralica degenerativa
- Un centro di riferimento per il trattamento riparativo della patologia mitralica non può prescindere dal conoscere il proprio «repair rate» e l'outcome a distanza dei pazienti trattati
- La stabilità nel tempo della riparazione valvolare mitralica in relazione alla tecnica utilizzata e al risultato postoperatorio precoce meritano ulteriore approfondimento